Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Netarsudil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 known ✓ | O75116 | 19/20 | 1.00 |
| ▸ | ROCK1 known ✓ | Q13464 | 6/20 | 1.00 |
| ▸ | MYLK4 | Q86YV6 | 2/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Netarsudil SCHEMBL19897392 | 1.00 | ROCK2 (1.00) | ROCK2ROCK1MYLK4 | |
| Netarsudil SCHEMBL114348 | 1.00 | ROCK2 (1.00) | ROCK2ROCK1MYLK4 | |
| Netarsudil SCHEMBL113753 | 1.00 | ROCK2 (1.00) | ROCK2ROCK1MYLK4 | |
| Netarsudil SCHEMBL29731235 | 1.00 | ROCK2 (1.00) | ROCK2ROCK1MYLK4 | |
| Netarsudil SCHEMBL29673273 | 0.99 | ROCK2 (1.00) | ROCK2ROCK1MYLK4 | |
| Netarsudil SCHEMBL16036278 | 0.99 | ROCK2 (1.00) | ROCK2ROCK1MYLK4 | |
| Netarsudil SCHEMBL29351219 | 0.99 | ROCK2 (1.00) | ROCK2ROCK1MYLK4 | |
| Netarsudil SCHEMBL16037348 | 0.99 | ROCK2 (1.00) | ROCK2ROCK1MYLK4 | |
| Netarsudil SCHEMBL21679903 | 0.99 | ROCK2 (1.00) | ROCK2ROCK1MYLK4 | |
| Netarsudil SCHEMBL114266 | 0.99 | ROCK2 (1.00) | ROCK2ROCK1MYLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260027105-A1 | COMPOUND MEDICINE COMPOSITION FOR TREATING GLAUCOMA AND USE OF SAME | SHENYANG PHARMACEUTICAL UNIVERSITY (CN) | 2026-01-29 | — | — | US | claimed |
| US-20250206845-A1 | PHARMACEUTICAL COMPOSITION INCLUDING RHO-KINASE INHIBITOR FOR PREVENTION OR TREATMENT OF CUTANEOUS FIBROTIC DISORDERS SUCH AS KELOID, ETC. AND USE THEREOF | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) | 2025-06-26 | — | — | US | claimed |
| EP-4527387-A1 | COMPOUND PHARMACEUTICAL COMPOSITION FOR TREATING GLAUCOMA AND USE THEREOF | Shenyang Pharmaceutical University (CN) | 2025-03-26 | — | — | EP | claimed |
| WO-2023182856-A1 | PHARMACEUTICAL COMPOSITION INCLUDING RHO-KINASE INHIBITOR FOR PREVENTION OR TREATMENT OF CUTANEOUS FIBROTIC DISORDERS SUCH AS KELOID, ETC. AND USE THEREOF | 서울대학교산학협력단 | 2023-09-28 | — | — | WO | claimed |
| US-20260027105-A1 | COMPOUND MEDICINE COMPOSITION FOR TREATING GLAUCOMA AND USE OF SAME | SHENYANG PHARMACEUTICAL UNIVERSITY (CN) | 2026-01-29 | — | — | US | disclosed |
| US-12522804-B2 | Method for producing pancreatic β cells | KANEKA CORPORATION (JP) | 2026-01-13 | — | — | US | disclosed |
| US-12479866-B2 | Boron-containing rho kinase inhibitors | PERCIPIAD, INC. | 2025-11-25 | — | — | US | disclosed |
| EP-3999072-B1 | BORON-CONTAINING RHO KINASE INHIBITORS | PERCIPIAD INC (US) | 2025-08-27 | — | — | EP | disclosed |
| US-20250206845-A1 | PHARMACEUTICAL COMPOSITION INCLUDING RHO-KINASE INHIBITOR FOR PREVENTION OR TREATMENT OF CUTANEOUS FIBROTIC DISORDERS SUCH AS KELOID, ETC. AND USE THEREOF | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) | 2025-06-26 | — | — | US | disclosed |
| EP-4527387-A1 | COMPOUND PHARMACEUTICAL COMPOSITION FOR TREATING GLAUCOMA AND USE THEREOF | Shenyang Pharmaceutical University (CN) | 2025-03-26 | — | — | EP | disclosed |
| US-20240418707-A1 | SELF-ORGANIZING NEURO-MUSCULAR JUNCTION CELL CULTURE MODEL | MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN IN DER HELMHOLTZ-GEMEINSCHAFT (DE) | 2024-12-19 | — | — | US | disclosed |
| CN-118873533-A | Ophthalmic composition | 爱尔康公司 | 2024-11-01 | — | — | CN | disclosed |
| US-8394826-B2 | Dual mechanism inhibitors for the treatment of disease | AERIE PHARMACEUTICALS, INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-20120135984-A1 | DUAL-ACTION INHBITORS AND METHODS OF USING SAME | AERIE PHARMACEUTICALS, INC. | 2012-05-31 | — | — | US | disclosed |
| EP-2424857-A1 | DUAL-ACTION INHIBITORS AND METHODS OF USING SAME | Aerie Pharmaceuticals, Inc. (US) | 2012-03-07 | — | — | EP | disclosed |
| EP-2424842-A2 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | Aerie Pharmaceuticals, Inc. (US) | 2012-03-07 | — | — | EP | disclosed |
| US-20100280011-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | ALCON INC. (CH) | 2010-11-04 | — | — | US | disclosed |
| WO-2010127329-A1 | DUAL-ACTION INHIBITORS AND METHODS OF USING SAME | AERIE PHARMACEUTICALS, INC. (US) | 2010-11-04 | — | — | WO | disclosed |
| WO-2010127330-A1 | DUAL-ACTION INHIBITORS AND METHODS OF USING SAME | AERIE PHAMACEUTICALS, INC. (US) | 2010-11-04 | — | — | WO | disclosed |
| WO-2010126626-A2 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | AERIE PHARMACEUTICALS, INC. (US) | 2010-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260027105-A1 | COMPOUND MEDICINE COMPOSITION FOR TREATING GLAUCOMA AND USE OF SAME | PTGIR, ADRB1, ADRB2 | ROCK2 180/4885ROCK1 67/4885MYLK4 122/4885 |
| US-20120135984-A1 | DUAL-ACTION INHBITORS AND METHODS OF USING SAME | SLC6A2, ROCK2, SLC6A4 | ROCK2 2/4885ROCK1 6/4885MYLK4 196/4885 |
| US-20100280011-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | RHOA, SLC6A2, ROCK2 | ROCK2 3/4885ROCK1 10/4885MYLK4 146/4885 |
| US-12479866-B2 | Boron-containing rho kinase inhibitors | ROCK1, ROCK2, RHOT2 | ROCK2 2/4885ROCK1 1/4885MYLK4 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.